Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.68) by 55.88 percent. This is a 783.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $176.200 million which beat the analyst consensus estimate of $166.122 million by 6.07 percent. This is a 37.89 percent increase over sales of $127.785 million the same period last year.